Livasa Hospitals appoints Kamal Kant Gambhir as Chief Financial Officer

Gambhir brings over 35 years of rich experience in strategic finance, governance, business transformation, and leadership

Asahi Kasei pushes into human trials with new autoimmune drug candidate

The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp

Asahi Kasei seals Aicuris acquisition to bolster infectious disease pharma push

The deal the group says marks a decisive push deeper into severe infectious diseases and the build-out of a global specialty pharmaceuticals platform

NASA’s Artemis II mission to on board Opella’s Dulcolax for lunar orbit mission

A brand from Opella will be part of the official NASA astronaut formulary

AptarGroup nasal spray tech joins ENA respiratory’s Phase II trial of INNA?051

The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention

Glenmark Therapeutics USA launches fluticasone propionate nasal spray

The Flonase Allergy Relief Nasal Spray, 50 mcg per spray market achieved annual sales of approximately $384.7 million

Lupin Manufacturing Solutions announces expansion of Dabhasa facility

These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions

Esperion to acquire Corstasis, gaining first FDA-approved nasal spray Diuretic

Asahi Kasei secures global rights to novel Alchemedicine preclinical compounds

Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients

Asahi Kasei to acquire German biopharmaceutical company Aicuris for €780 million

Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups